RESEARCHER PROFILE

Matthias Pinter

← Back to Medical University of Vienna

M

Medical University of Vienna

Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and StudiesCancer Immunotherapy and BiomarkersLiver Disease and TransplantationLiver Disease Diagnosis and Treatment

Matthias Pinter works in Hepatocellular Carcinoma Treatment and Prognosis, Colorectal Cancer Treatments and Studies, Cancer Immunotherapy and Biomarkers, Liver Disease and Transplantation, Liver Disease Diagnosis and Treatment. Recorded institutional associations include Vienna General Hospital, Medical University of Vienna.

482Publications
12,402Citations
57H-index

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. NASH limits anti-tumour surveillance in immunotherapy-treated HCC

    2021 · 1,280 citations
  2. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

    2023 · 536 citations
  3. Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy

    2016 · 456 citations
  4. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial

    2025 · 373 citations
  5. The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma

    2013 · 343 citations
  6. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol

    2012 · 342 citations
  7. The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma

    2020 · 339 citations
  8. Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy

    2017 · 332 citations
  9. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score

    2021 · 303 citations
  10. Cancer and liver cirrhosis: implications on prognosis and management

    2016 · 295 citations
  11. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study

    2022 · 235 citations
  12. Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups

    2020 · 233 citations
  13. Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2

    2018 · 221 citations
  14. Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality

    2020 · 211 citations
  15. Advanced-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization versus Sorafenib

    2012 · 197 citations
  16. Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma

    2018 · 190 citations
  17. Sorafenib in Unresectable Hepatocellular Carcinoma from Mild to Advanced Stage Liver Cirrhosis

    2009 · 178 citations
  18. Review article: systemic treatment of hepatocellular carcinoma

    2018 · 160 citations
  19. Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon‐Free Therapy

    2019 · 160 citations
  20. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma

    2014 · 159 citations
  21. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.

    2024 · 151 citations
  22. Targeting CXCR4-dependent immunosuppressive Ly6C low monocytes improves antiangiogenic therapy in colorectal cancer

    2017 · 138 citations
  23. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease

    2021 · 135 citations
  24. Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma

    2012 · 132 citations
  25. Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice

    2023 · 132 citations

← Return to the university profile